Neuropathological and vascular determinants of cerebral amyloid angiopathy risk: evidence from the NACC cohort

Alzheimer’s Research & Therapy · Published 2026-08-01 · DOI 10.1186/s13195-026-02064-x

Free full text

Authors (5)

Liwei Ma, Yihan Wang, Benjamin Goudey, Liang Jin, Yijun Pan

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Ma, L., Wang, Y., Goudey, B., et al. (2026). Neuropathological and vascular determinants of cerebral amyloid angiopathy risk: evidence from the NACC cohort. Alzheimer’s Research & Therapy. https://doi.org/10.1186/s13195-026-02064-x

Related articles

• Smoking cessation duration and risk of Alzheimer’s disease: a nationwide cohort study in Korea · Alzheimer’s Research & Therapy · 2026 · Same journal
• Uncovering lipid biomarkers linked to methylphenidate efficacy in treating apathy in Alzheimer’s disease: insights from the ADMET 2 trial · Alzheimer’s Research & Therapy · 2026 · Same journal
• Neural changes after computerized cognitive training in coronary heart disease with mild cognitive impairment: secondary analysis of a randomized clinical trial · Alzheimer’s Research & Therapy · 2026 · Same journal
• Clarifying comparative claims in digital cognitive assessment: a matters arising on multimodal detection of cognitive impairment and amyloid positivity · Alzheimer’s Research & Therapy · 2026 · Same journal
• Sequential associations of myelin dysfunction with Aβ and Tau pathology in Alzheimer's disease: a dynamic myelin perturbation · Alzheimer’s Research & Therapy · 2026 · Same journal
• Resting-state functional dynamics alterations relate to plasma amyloid markers and statistically explain memory impairments in the TgF344-AD model of Alzheimer’s disease · Alzheimer’s Research & Therapy · 2026 · Same journal
• Thresholds for meaningful change in Mini-Mental State Examination scores in rare dementias · Alzheimer’s Research & Therapy · 2026 · Same journal
• Plasma ApoE proteotyping for ApoE ε4 stratification in the anti-amyloid therapies era · Alzheimer’s Research & Therapy · 2026 · Same journal
• Safety, tolerability and immunogenicity of vaccine ALZ-101 in patients with early Alzheimer’s disease: randomised, controlled trial · Alzheimer’s Research & Therapy · 2026 · Same journal
• Plasma p-tau as a biomarker for the differential diagnosis of Alzheimer’s disease: a systematic review and meta-analysis · Alzheimer’s Research & Therapy · 2026 · Same journal